17 results on '"Jacqz-Aigrain, Evelyne"'
Search Results
2. Limited sampling strategy and population pharmacokinetic model of mycophenolic acid in pediatric patients with systemic lupus erythematosus: application of a double gamma absorption model with SAEM algorithm.
- Author
-
Koloskoff, Kévin, Benito, Sylvain, Chambon, Lucie, Dayan, Frédéric, Marquet, Pierre, Jacqz-Aigrain, Evelyne, and Woillard, Jean-Baptiste
- Subjects
ABSORPTION ,STRATEGIC planning ,MATHEMATICAL models ,MYCOPHENOLIC acid ,HUMAN services programs ,COMPARATIVE studies ,PHARMACEUTICAL arithmetic ,THEORY ,DESCRIPTIVE statistics ,RESEARCH funding ,SYSTEMIC lupus erythematosus ,STATISTICAL sampling ,DEMOGRAPHIC characteristics ,ALGORITHMS ,DRUG administration ,DRUG dosage ,CHILDREN - Abstract
Introduction: Mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil (MMF), is widely used in the treatment of systemic lupus erythematosus (SLE). It has been shown that its therapeutic drug monitoring based on the area under the curve (AUC) improves treatment efficacy. MPA exhibits a complex bimodal absorption, and a double gamma distribution model has been already proposed in the past to accurately describe this phenomenon. These previous population pharmacokinetics models (POPPK) have been developed using iterative two stage Bayesian (IT2B) or non-parametric adaptive grid (NPAG) methods. However, non-linear mixed effect (NLME) approaches based on stochastic approximation expectation–maximization (SAEM) algorithms have never been published so far for this particular model. The objectives of this study were (i) to implement the double absorption gamma model in Monolix, (ii) to compare different absorption models to describe the pharmacokinetics of MMF, and (iii) to develop a limited sampling strategy (LSS) to estimate AUC in pediatric SLE patients. Material and methods: A data splitting of full pharmacokinetic profiles sampled in 67 children extracted either from the expert system ISBA (n = 34) or the hospital Saint Louis (n = 33) was performed into train (75%) and test (25%) sets. A POPPK was developed for MPA in the train set using a NLME and the SAEM algorithm and different absorption models were implemented and compared (first order, transit, or simple and double gamma). The best limited sampling strategy was then determined in the test set using a maximum-a-posteriori Bayesian method to estimate individual PK parameters and AUC based on three blood samples compared to the reference AUC calculated using the trapezoidal rule applied on all samples and performances were assessed in the test set. Results: Mean patient age and dose was 13 years old (5–18) and 18.1 mg/kg (7.9–47.6), respectively. MPA concentrations (764) from 107 occasions were included in the analysis. A double gamma absorption with a first-order elimination from the central compartment best fitted the data. The optimal LSS with samples at 30 min, 2 h, and 3 h post-dose exhibited good performances in the test set (mean bias − 0.32% and RMSE 21.0%). Conclusion: The POPPK developed in this study adequately estimated the MPA AUC in pediatric patients with SLE based on three samples. The double absorption gamma model developed with the SAEM algorithm showed very accurate fit and reduced computation time. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Extremely low dose of 6‐mercaptopurine in a Chinese child with acute lymphoblastic leukaemia and multiple pharmacogenetic mutations.
- Author
-
Zhai, Xiao‐Ying, Zhou, Yue, Dong, Lei, Nie, Ai‐Qing, Zhi, Li‐Juan, Jacqz‐Aigrain, Evelyne, Wang, Tian‐You, Wang, Li, and Zhao, Wei
- Subjects
ANTIMETABOLITES ,DRUG monitoring ,LEUCOPENIA ,LYMPHOBLASTIC leukemia ,GENETIC mutation ,PHARMACOGENOMICS ,DISEASE risk factors ,CHILDREN - Abstract
What is known and objectives: Thiopurines are cornerstone drugs in the treatment of acute lymphoblastic leukaemia (ALL), but their use can be complicated by the incidence of life‐threatening leucopenia. Case description: We describe a case of a 6‐year‐old Chinese boy with B‐ALL receiving extremely low dose of 6‐mercaptopurine (only 4% of recommended dose) during the ALL maintenance therapy phase. What is new and conclusion: Complex pharmacogenetic tests and TDM should be recommended in children with complicated ALL to highlight the large individual variability in the responses to 6‐MP exposure and the associated adverse effects. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Off‐label use of tacrolimus in children with glomerular disease: Effectiveness, safety and pharmacokinetics.
- Author
-
Hao, Guo‐Xiang, Song, Lin‐Lin, Zhang, Dong‐Feng, Su, Le‐Qun, Jacqz‐Aigrain, Evelyne, and Zhao, Wei
- Subjects
JUVENILE diseases ,PEDIATRIC therapy ,CHRONIC kidney failure ,THERAPEUTICS ,LUPUS nephritis - Abstract
Glomerular diseases are leading causes of end‐stage renal disease in children. Tacrolimus is frequently used off‐label in the treatment of glomerular diseases. The effectiveness, safety and pharmacokinetic data of tacrolimus in the treatment of glomerular diseases in children are reviewed in this paper to provide evidence to support its rational use in clinical practice. The remission rates in previously published studies were different. In 19 clinical trials on children with nephrotic syndrome, the overall remission rate was 52.6‐97.6%. In four clinical trials on children with lupus nephritis, the overall remission rate was 81.8‐89.5%. In a pilot study with paediatric Henoch‐Schönlein purpura nephritis patients, the overall remission rate was 100.0%. Infection, nephrotoxicity, gastrointestinal symptoms and hypertension are the most common adverse events. Body weight, age, CYP3A5 genotype, cystatin‐C and daily dose of tacrolimus may have significant effects on the pharmacokinetics of tacrolimus in children with glomerular disease. More prospective controlled trials with long follow‐up are needed to demonstrate definitely the effectiveness, safety and pharmacokinetics of tacrolimus in children with glomerular diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings
- Author
-
Zhao, Wei, Kaguelidou, Florentia, Biran, Valérie, Zhang, Daolun, Allegaert, Karel, Capparelli, Edmund, van den Anker, John, Fakhoury, May, and Jacqz-Aigrain, Evelyne
- Subjects
RENAL-FUNCTION ,Science & Technology ,PRETERM ,PREDICTION ,vancomycin ,INFANTS ,CHILDREN ,QUANTIFICATION ,REGIMENS ,neonates ,serum creatinine ,external evaluation ,population pharmacokinetics ,Pharmacology & Pharmacy ,dosing regimen ,Life Sciences & Biomedicine ,CREATININE - Abstract
BACKGROUND: Vancomycin is one of the most evaluated antibiotics in neonates using modeling and simulation approaches. However no clear consensus on optimal dosing has been achieved. The objective of the present study was to perform an external evaluation of published models, in order to test their predictive performances in an independent dataset and to identify the possible study-related factors influencing the transferability of pharmacokinetic models to different clinical settings. METHOD: Published neonatal vancomycin pharmacokinetic models were screened from the literature. The predictive performance of 6 models was evaluated using an independent dataset (112 concentrations from 78 neonates). The evaluation procedures used simulation-based diagnostics (visual predictive check [VPC] and normalized prediction distribution errors [NPDE]). RESULTS: Differences in predictive performances of models for vancomycin pharmacokinetics in neonates were found. The mean of NPDE for 6 evaluated models were 1.35, -0.22, -0.36, 0.24, 0.66, 0.48, respectively. These differences were explained, at least partly, by taking into account the method used to measure serum creatinine concentrations. The adult conversion factor of 1.3 (enzymatic to Jaffé) was tested with an improvement in the VPC and NPDE, but it still need to be evaluated and validated in neonates. Differences were also identified between analytical methods for vancomycin. CONCLUSION: The importance of analytical techniques for serum creatinine concentrations and vancomycin as a predictor of vancomycin concentrations in neonates has been confirmed. Dosage individualisation of vancomycin in neonates should consider not only patients' characteristics and clinical conditions, but also the methods used to measure serum creatinine and vancomycin. ispartof: British Journal of Clinical Pharmacology vol:75 issue:4 pages:1068-1080 ispartof: location:England status: published
- Published
- 2013
6. Population pharmacokinetics of tacrolimus in children with nephrotic syndrome.
- Author
-
Hao, Guo‐Xiang, Huang, Xin, Zhang, Dong‐Feng, Zheng, Yi, Shi, Hai‐Yan, Li, Yan, Jacqz‐Aigrain, Evelyne, and Zhao, Wei
- Subjects
NEPHROTIC syndrome in children ,PHARMACOKINETICS ,TACROLIMUS ,DRUG efficacy ,PHARMACODYNAMICS - Abstract
Aims: Nephrotic syndrome (NS) is the most common clinical manifestation of glomerular disease in children. Currently, tacrolimus (TAC) is widely used in children with NS. However, pharmacokinetic data in children with nephrotic syndrome is limited. This study was intended to evaluate the population pharmacokinetics (PPK) of TAC in paediatric NS and to optimize dosing regimen. Methods: Blood samples from NS children treated with TAC were collected and the blood concentrations of TAC were detected using HPLC‐MS/MS. A PPK model was developed using NONMEM software. Pharmacogenetic analysis was carried out in the CYP3A5 gene. Results: The data from 28 children were used for PPK analysis. A one‐compartment model and first‐order elimination were accorded with the TAC data in paediatric NS. A covariate analysis showed that body weight and CYP3A5 genotype significantly affected TAC pharmacokinetics. Monte Carlo simulation indicated that NS children with CYP3A5*3/*3 receiving 0.10 mg kg
−1 dose−1 twice daily and NS children with CYP3A5*1 receiving 0.25 mg kg−1 dose−1 twice daily TAC could achieve the target concentrations of 5–10 ng ml−1 . Conclusion: The PPK of TAC was estimated in children with NS and a CYP3A5 genotype‐based dosing regimen was set up based on simulations. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
7. Off-label use of tacrolimus in children with Henoch-Schönlein purpura nephritis: a pilot study.
- Author
-
Dong-Feng Zhang, Guo-Xiang Hao, Chun-Zhen Li, Yan-Jun Yang, Fu-Juan Liu, Ling Liu, Xiao-Ying Yuan, Rui-Hong Li, Lei Dong, Qian Dong, Jacqz-Aigrain, Evelyne, Wei Zhao, Zhang, Dong-Feng, Hao, Guo-Xiang, Li, Chun-Zhen, Yang, Yan-Jun, Liu, Fu-Juan, Liu, Ling, Yuan, Xiao-Ying, and Li, Rui-Hong
- Subjects
TACROLIMUS ,SCHOENLEIN-Henoch purpura ,DRUG efficacy ,NEPHRITIS ,CHILDREN - Abstract
Background: Tacrolimus is used off-label in the treatment of Henoch-Schönlein purpura nephritis (HSPN) in children, with limited evidence-based data. Based on clinical empirical experience and mechanism of action, tacrolimus might be promoted as treatment for childhood HSPN. The objectives of this pilot study were to assess its effectiveness and safety, and to explore the potential impact of CYP3A5 genotype.Methods: Children with HSPN receiving tacrolimus as empirical treatment were included in this prospective, observational study. Effectiveness was classified as complete remission, partial remission or non-response. General safety data analyses during and after study drug exposure included adverse events, reasons for discontinuation, deaths, laboratory data and vital signs. Trough concentration was determined using high-performance liquid chromatography with tandem mass spectrometry. Pharmacogenetic analysis was performed on the CYP3A5 gene.Results: A total of 20 patients with a mean age of 7.5 (SD 2.1) years participated in the whole process of the study. Twelve patients reached complete remission and eight patients reached partial remission at the end of 6-month treatment. No patients discontinued tacrolimus treatment due to adverse events, and no drug-related adverse events were shown to have a causal association with tacrolimus therapy. Dose-adjusted trough concentration was significantly higher in children with CYP3A5*1 allele as compared with patients with CYP3A5*3/*3 genotype (170.7±100.9 vs 79.8±47.4 (ng/mL)/(mg/kg)).Conclusion: This pilot study showed that tacrolimus might be an effective and well-tolerated drug for the treatment of HSPN in children. CYP3A5 polymorphism had a significant impact on tacrolimus concentration. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
8. Pharmacogenetics of post-transplant diabetes mellitus in children with renal transplantation treated with tacrolimus.
- Author
-
Lancia, Pauline, Adam de Beaumais, Tiphaine, Elie, Valéry, Garaix, Florentine, Fila, Marc, Nobili, François, Ranchin, Bruno, Testevuide, Pascale, Ulinski, Tim, Zhao, Wei, Deschênes, Georges, and Jacqz-Aigrain, Evelyne
- Subjects
DIABETES risk factors ,TACROLIMUS ,AGE distribution ,DIABETES ,GENETIC polymorphisms ,HOMEOSTASIS ,KIDNEY transplantation ,MEDICAL care ,MEDICAL cooperation ,PATIENTS ,PHARMACOGENOMICS ,RESEARCH ,SEX distribution ,SURGICAL complications ,DISEASE duration ,GENOTYPES ,CHILDREN ,THERAPEUTICS - Abstract
Background: Post-transplant diabetes mellitus (PTDM) is a major complication of immunosuppressive therapy, with many risk factors reported in adults with renal transplantation. The objective of this study was to investigate potential non-genetic and genetic risk factors of PTDM in children with renal transplantation treated with tacrolimus.Methods: A national database was screened for patients developing PTDM within 4 years following tacrolimus introduction. PTDM was defined as glucose disorder requiring anti-diabetic treatment. PTDM patients were matched to “non-PTDM” control transplanted children according to age, gender, and duration of post-transplant follow-up. Patients were genotyped for six selected genetic variants in
POR*28 (rs1057868),PPARa (rs4253728),CYP3A5 (rs776746),VDR (rs2228570 and rs731236), andABCB1 (rs1045642) genes, implicated in glucose homeostasis and tacrolimus disposition.Results: Among the 98 children with renal transplantation enrolled in this multicentre study, 18 developed PTDM. None of the clinical and biological parameters was significant between PTDM and control patients. Homozygous carriers ofPOR*28 or wild-typeABCB1 (rs1045642) gene variants were more frequent in PTDM than in control patients with differences close to significance (p = 0.114 andp = 0.066 respectively). A genetic score based on these variants demonstrated thatPOR*28/*28 andABCB1 CC or CT genotype carriers were at a significantly higher risk of developing PTDM after renal transplantation.Conclusion: Identification of PTDM risk factors should allow clinicians to allocate the best immunosuppressant for each patient with renal transplantation, and improve care for patients who are at a higher risk. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
9. Predicting CYP3A‐mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure.
- Author
-
Brussee, Janneke M., Vet, Nienke J., Krekels, Elke H. J., Valkenburg, Abraham J., Jacqz‐Aigrain, Evelyne, van Gerven, Joop M. A., Swart, Eleonora L., van den Anker, Johannes N., Tibboel, Dick, de Hoog, Matthijs, de Wildt, Saskia N., and Knibbe, Catherijne A. J.
- Subjects
CYTOCHROME P-450 ,MIDAZOLAM ,CRITICALLY ill children ,INFLAMMATION ,MULTIPLE organ failure ,PHARMACOKINETICS - Abstract
Aims: Inflammation and organ failure have been reported to have an impact on cytochrome P450 (CYP) 3A‐mediated clearance of midazolam in critically ill children. Our aim was to evaluate a previously developed population pharmacokinetic model both in critically ill children and other populations, in order to allow the model to be used to guide dosing in clinical practice. Methods: The model was evaluated externally in 136 individuals, including (pre)term neonates, infants, children and adults (body weight 0.77–90 kg, C‐reactive protein level 0.1–341 mg l
–1 and 0–4 failing organs) using graphical and numerical diagnostics. Results: The pharmacokinetic model predicted midazolam clearance and plasma concentrations without bias in postoperative or critically ill paediatric patients and term neonates [median prediction error (MPE) <30%]. Using the model for extrapolation resulted in well‐predicted clearance values in critically ill and healthy adults (MPE <30%), while clearance in preterm neonates was over predicted (MPE >180%). Conclusion: The recently published pharmacokinetic model for midazolam, quantifying the influence of maturation, inflammation and organ failure in children, yields unbiased clearance predictions and can therefore be used for dosing instructions in term neonates, children and adults with varying levels of critical illness, including healthy adults, but not for extrapolation to preterm neonates. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
10. Impact of Glutathione S-Transferase M1 and T1 on Anti-Tuberculosis Drug–Induced Hepatotoxicity in Chinese Pediatric Patients.
- Author
-
Liu, Fang, Jiao, An-xia, Wu, Xi-rong, Zhao, Wei, Yin, Qing-qin, Qi, Hui, Jiao, Wei-wei, Xiao, Jing, Sun, Lin, Shen, Chen, Tian, Jian-ling, Shen, Dan, Jacqz-Aigrain, Evelyne, and Shen, A-dong
- Subjects
DRUG side effects ,HEPATOTOXICOLOGY ,ANTITUBERCULAR agents ,GLUTATHIONE ,DETOXIFICATION (Alternative medicine) ,CHILDREN ,JUVENILE diseases - Abstract
Background: Anti-tuberculosis drug induced hepatotoxicity (ATDH) is a major adverse drug reaction associated for anti-tuberculosis therapy. The glutathione S-transferases (GST) plays a crucial role in the detoxification of hepatotoxic metabolites of anti-tuberculosis drugs.An association between GSTM1/GSTT1 null mutations and increased risk of ATDH has been demonstrated in adults. Given the ethnic differences and developmental changes, our study aims to investigate the potential impacts of GSTM1/GSTT1genotypes on the development of ATDH in Han Chinese children treated with anti-tuberculosis therapy. Methods: Children receiving anti-tuberculosis therapy with or without evidence of ATDH were considered as the cases or controls, respectively. The GSTM1 and GSTT1 genotyping were performed using the polymerase chain reaction. Results: One hundred sixty-three children (20 cases and 143 controls) with a mean age of 4.7 years (range: 2 months-14.1 years) were included. For the GSTM1, 14 (70.0%) cases and 96 (67.1%) controls had homozygous null mutations. For the GSTT1, 13 (65.0%) cases and 97 (67.8%) controls had homozygous null mutations. Neither the GSTM1, nor the GSTT1 polymorphism was significantly correlated with the occurrence of ATHD. Conclusion: Ourresults did not support the GSTM1 and GSTT1 polymorphisms as the predictors of ADTH in Chinese Han children treated with anti-tuberculosis drugs. An age-related association between pharmacogenetics and ATHD need to be confirmed in the further study. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
11. Safety of fluconazole in paediatrics: a systematic review.
- Author
-
Egunsola, Oluwaseun, Adefurin, Abiodun, Fakis, Apostolos, Jacqz-Aigrain, Evelyne, Choonara, Imti, and Sammons, Helen
- Subjects
CANDIDIASIS ,CINAHL database ,CONFIDENCE intervals ,DRUG interactions ,DRUG toxicity ,GASTROINTESTINAL system ,HEPATOTOXICOLOGY ,PREMATURE infants ,MEDICAL databases ,INFORMATION storage & retrieval systems ,MEDICAL information storage & retrieval systems ,MEDLINE ,META-analysis ,NYSTATIN ,PATIENT safety ,REGRESSION analysis ,RESEARCH funding ,SYSTEMATIC reviews ,DATA analysis software ,DESCRIPTIVE statistics ,CHILDREN ,FLUCONAZOLE ,THERAPEUTICS - Abstract
Purpose: To determine the safety of fluconazole in neonates and other paediatric age groups by identifying adverse events (AEs) and drug interactions associated with treatment. Methods: A search of EMBASE (1950-January 2012), MEDLINE (1946-January 2012), the Cochrane database for systematic reviews and the Cumulative Index to Nursing and Allied Health Literature (1982-2012) for any clinical study about fluconazole use that involved at least one paediatric patient (≤17 years) was performed. Only articles with sufficient quality of safety reporting after patients' exposure to fluconazole were included. Results: We identified 90 articles, reporting on 4,209 patients, which met our inclusion criteria. In total, 794 AEs from 35 studies were recorded, with hepatotoxicity accounting for 378 (47.6 %) of all AEs. When fluconazole was compared with placebo and other antifungals, the relative risk (RR) of hepatotoxicity was not statistically different [RR 1.36, 95 % confidence interval (CI) 0.87-2.14, P = 0.175 and RR 1.43, 95 % CI 0.67-3.03, P = 0.352, respectively]. Complete resolution of hepatoxicity was achieved by 84 % of patients with follow-up available. There was no statistical difference in the risk of gastrointestinal events of fluconazole compared with placebo and other antifungals (RR 0.81, 95 % CI 0.12-5.60, P = 0.831 and RR 1.23, 95 %CI 0.87-1.71, P = 0.235, respectively). There were 41 drug withdrawals, 17 (42 %) of which were due to elevated liver enzymes. Five reports of drug interactions occurred in children. Conclusion: Fluconazole is relatively safe for paediatric patients. Hepatotoxicity and gastrointestinal toxicity are the most common adverse events. It is important to be aware that drug interactions with fluconazole can result in significant toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
12. Prevention of Nosocomial Infections in Neonatal Intensive Care Units.
- Author
-
Manzoni, Paolo, De Luca, Daniele, Stronati, Mauro, Jacqz-Aigrain, Evelyne, Ruffinazzi, Giulia, Luparia, Martina, Tavella, Elena, Boano, Elena, Castagnola, Elio, Mostert, Michael, and Farina, Daniele
- Subjects
NEONATAL intensive care ,BREAST milk ,SEPTICEMIA prevention ,CROSS infection prevention ,THERAPEUTIC use of probiotics ,PREVENTION of communicable diseases ,HEALTH outcome assessment ,NEONATAL diseases ,PNEUMONIA ,SEPSIS ,MECHANICAL ventilators ,NEONATAL intensive care units ,TREATMENT effectiveness ,DISEASE complications ,CHILDREN ,PREVENTION ,THERAPEUTICS - Abstract
Neonatal sepsis causes a huge burden of morbidity and mortality and includes bloodstream, urine, cerebrospinal, peritoneal, and lung infections as well as infections starting from burns and wounds, or from any other usually sterile sites. It is associated with cytokine - and biomediator-induced disorders of respiratory, hemodynamic, and metabolic processes. Neonates in the neonatal intensive care unit feature many specific risk factors for bacterial and fungal sepsis. Loss of gut commensals such as Bifidobacteria and Lactobacilli spp., as occurs with prolonged antibiotic treatments, delayed enteral feeding, or nursing in incubators, translates into proliferation of pathogenic microflora and abnormal gut colonization. Prompt diagnosis and effective treatment do not protect septic neonates form the risk of late neurodevelopmental impairment in the survivors. Thus prevention of bacterial and fungal infection is crucial in these settings of unique patients. In this view, improving neonatal management is a key step, and this includes promotion of breast-feeding and hygiene measures, adoption of a cautious central venous catheter policy, enhancement of the enteric microbiota composition with the supplementation of probiotics, and medical stewardship concerning H2 blockers with restriction of their use. Additional measures may include the use of lactoferrin, fluconazole, and nystatin and specific measures to prevent ventilator associated pneumonia. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
13. Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.
- Author
-
Adam de Beaumais, Tiphaine and Jacqz-Aigrain, Evelyne
- Subjects
- *
HEPATOTOXICOLOGY , *ANTIMETABOLITES , *CARRIER proteins , *GENETIC polymorphisms , *HYDROLASES , *LYMPHOBLASTIC leukemia , *HEALTH outcome assessment , *OXIDOREDUCTASES , *TRANSFERASES , *TREATMENT effectiveness , *CHILDREN , *PREVENTION - Abstract
Background: The backbone of drug therapy used in acute lymphoblastic leukemia (ALL) in children includes 6-mercaptopurine (6-MP). Intracellular metabolism of this prodrug is a key component of the therapeutic response. Many metabolizing enzymes are involved in 6-MP disposition and active 6-MP metabolites are represented by 6-thioguanine nucleotides (6-TGN) and methylated metabolites primarily methylated by the thiopurine S-methyltransferase enzyme (TPMT). The genetic polymorphism affecting TPMT activity displays an important inter-subject variability in metabolites pharmacokinetics and influences the balance between 6-MP efficacy and toxicity: patients with high 6-TGN levels are at risk of myelosuppression while patients with high levels of methylated derivates are at hepatotoxic risk. However, the genetic TPMT polymorphism does not explain all 6-MP adverse events and some severe toxicities leading to life-threatening conditions remain unexplained. Additional single nucleotide polymorphisms (SNPs) in genes encoding enzymes involved in 6-MP metabolism and 6-MP transporters may also be responsible for this inter-individual 6-MP response variability. Aim: This review presents the pharmacogenetic aspects of 6-MP metabolism in great detail. We have focused on published data on ALL treatment supporting the great potential of 6-MP pharmacogenetics to improve efficacy, tolerance, and event-free survival rates in children with ALL. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
14. Integration of Pharmacogenetics and Pharmacogenomics in Drug Development: Implications for Regulatory and Medical Decision Making in Pediatric Diseases.
- Author
-
Piana, Chiara, Surh, Linda, Furst-Recktenwald, Sabine, Iolascon, Achille, Jacqz-Aigrain, Evelyne M., Jonker, Ineke, Russo, Roberta, van Schaik, Ron H.N., Wessels, Judith, and Della Pasqua, Oscar E.
- Subjects
BIOMARKERS ,CHILD development ,DRUG design ,GENETICS ,HUMAN growth ,HEALTH outcome assessment ,PEDIATRICS ,DECISION making in clinical medicine ,GENOMICS ,TREATMENT effectiveness ,CHILDREN - Abstract
This article aims to provide an overview of the current situation regarding pharmacogenetic and pharmacogenomic (PG) studies in pediatrics, with a special focus on the role of PG data in the regulatory decision-making process. Despite the gap in pharmacogenetic research due to the lack of translational studies in adults and children, several technologies exist in drug development and biomarkers validation, which could supply valuable information concerning labeling and dosing recommendations. If performed under strict good clinical practice quality criteria, such findings could be included in the submission package of new chemical entities and used as additional information for prescribers, supporting further evaluation and understanding of the efficacy and safety profile of new medicines. Even though regulatory authorities may be aware of the potential role of PG in medical practice and guidances are available about the integration of PG in drug development, most data obtained from PG studies are not used by prescribers. The challenge is to better understand whether PG markers can be used to assess potential differences in drug response during the clinical program, so PG data can be integrated into the regulatory decision-making process, enabling the introduction of labeling information that promotes optimal dosing in the pediatric population. [ABSTRACT FROM PUBLISHER]
- Published
- 2012
- Full Text
- View/download PDF
15. Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial.
- Author
-
Baudouin, Véronique, Alberti, Corinne, Lapeyraque, Anne-Laure, Bensman, Albert, André, Jean-Luc, Broux, Françoise, Cailliez, Mathilde, Decramer, Stéphane, Niaudet, Patrick, Deschênes, Georges, Jacqz-Aigrain, Evelyne, and Loirat, Chantal
- Subjects
COMBINATION drug therapy ,CLINICAL trials ,CONFIDENCE intervals ,NEPHROTIC syndrome ,HEALTH outcome assessment ,PREDNISONE ,RESEARCH funding ,STATISTICS ,U-statistics ,DISEASE relapse ,DATA analysis ,TREATMENT effectiveness ,DATA analysis software ,MYCOPHENOLIC acid ,DESCRIPTIVE statistics ,DRUG administration ,DRUG dosage ,CHILDREN ,THERAPEUTICS - Abstract
Mycophenolate mofetil (MMF) has emerged as a new therapeutic option in steroid-dependent nephrotic syndrome (SDNS). We conducted a phase II Bayesian trial of MMF in children with SDNS. Phase II trials, usually single-arm studies, investigate the effect of new treatments. Standard Fleming's procedure relies on observed results (relapse rate during the trial), whereas Bayesian approach combines observed results with prior information (expected relapse rate according to prior studies and clinical experience). All patients were required to have received prior alkylating-agent treatment. Sixty-seven percent of them had also received levamisole. Patients received MMF (1,200 mg/m/day) and prednisone according to a defined schedule [reduction of alternate-day (e.o.d) dose to 50% of pre-MMF dose at 3 months, 25% at 6 months]. Twenty-four children (median age 6.0 years, 2.8-14.4) entered the study and 23 completed it. Bayesian analysis showed that adding four patients would not change significance of results, allowing stopping inclusions. Four patients relapsed during the first 6 months (estimated probability 17.6%, 95% credibility interval: 5.4-35.0%) and two at months 8 and 11.5. In the 19 patients free of relapse during the first 6 months, median (Q1-Q3) prednisone maintenance dose decreased from 25 (10-44) to 9 (7.5-11.2) mg/m e.o.d ( p < 0.001) and cumulative dose from 459 (382-689) to 264 (196-306) mg/m/month ( p < 0.001) before and on MMF respectively. Pre-MMF patient characteristics and MMF pharmacokinetics did not differ between patients with or without relapse. MMF reduces relapse rate and steroid dose in children with SDNS and should be proposed before cyclosporine and cyclophosphamide. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
16. Population Pharmacokinetics and Pharmacogenetics of Mycophenolic Acid Following Administration of Mycophenolate Mofetil in De Novo Pediatric Renal-Transplant Patients.
- Author
-
Wei Zhao, Fakhoury, May, Deschênes, Georges, Roussey, Gwenaelle, Brochard, Karine, Niaudet, Patrick, Tsimaratos, Michel, Luc André, Jean, Cloarec, Sylvie, Cochat, Pierre, Bensman, Albert, Azougagh, Saïd, and Jacqz-Aigrain, Evelyne
- Subjects
IMMUNOSUPPRESSIVE agents ,GRAFT rejection prevention ,MYCOPHENOLIC acid ,ANALYSIS of variance ,COMPUTER software ,FISHER exact test ,GENETICS ,HIGH performance liquid chromatography ,IMMUNOSUPPRESSION ,KIDNEY transplantation ,PHARMACOKINETICS ,DATA analysis ,CHILDREN ,THERAPEUTICS - Abstract
The objective was to develop a population pharmacokinetic—pharmacogenetic model of mycophenolic acid following administration of mycophenolate mofetil (MMF) in de novo pediatric renal-transplant patients and identify factors that explain variability. The pharmacokinetic samples were collected from 89 de novo pediatric renal-transplant patients treated with MMF and studied during the first 60 postoperative days. All patients were genotyped for UGT1A8-A9, UGT2B7, and ABCC2. Population pharmacokinetic analysis was performed with the NONMEM and was validated using bootstrap visual predictive check. The pharmacokinetic data were best described by a 2-compartment model with Erlang distribution to describe the absorption phase. The covariate analysis identified body weight as an individual factor influencing central volume of distribution and concomitant immunosuppressive medication and identified body weight and UGT2B7 802C>T genotype as individual factors influencing apparent oral clearance (CL/F) of MMF. CL/F in cyclosporine-MMF—treated patients was 33% higher than in tacrolimus-MMF—treated patients. The CL/F was significantly lower in patients with UGT2B7 802 C/C genotype compared with patients with UGT2B7 802 C/T and 802T/T genotypes, and this effect was independent of concomitant immunosuppressive medication or body weight. The population pharmacokinetic—pharmacogenetic model of mycophenolic acid was validated. Body weight, concomitant medication, and UGT2B7 genotype contribute significantly to the interindividual variability of MMF disposition in pediatric renal-transplant patients. [ABSTRACT FROM PUBLISHER]
- Published
- 2010
- Full Text
- View/download PDF
17. Morphine Glucuronidation in Preterm Neonates, Infants and Children Younger than 3 Years.
- Author
-
Knibbe, Catherijne A. J., Krekels, Elke H. J., van den Anker, Johannes N., DeJongh, Joost, Santen, Gijs W. E., van Dijk, Monique, Simons, Sinno H. P., van Lingen, Richard A., Jacqz-Aigrain, Evelyne M., Danhof, Meindert, and Tibboel, Dick
- Subjects
MORPHINE ,NEWBORN infants ,CHILDREN ,DRUG dosage ,DRUG administration ,PHARMACOKINETICS - Abstract
Background and objective: A considerable amount of drug use in children is still unlicensed or off-label. In order to derive rational dosing schemes, the influence of aging on glucuronidation capacity in newborns, including preterms, infants and children under the age of 3 years was studied using morphine and its major metabolites as a model drug. Methods: A population pharmacokinetic model was developed with the nonlinear mixed-effects modelling software NONMEM® V, on the basis of 2159 concentrations of morphine and its glucuronides from 248 infants receiving intravenous morphine ranging in bodyweight from 500 g to 18 kg (median 2.8 kg). The model was internally validated using normalized prediction distribution errors. Results: Formation clearances of morphine to its glucuronides and elimination clearances of the glucuronides were found to be primarily influenced by bodyweight, which was parameterized using an allometric equation with an estimated exponential scaling factor of 1.44. Additionally, a postnatal age of less than 10 days was identified as a covariate for formation clearance to the glucuronides, independent of birthweight or postmenstrual age. Distribution volumes scaled linearly with bodyweight. Conclusions: Model-based simulations show that in newborns, including preterms, infants and children under the age of 3 years, a loading dose in μg/kg and a maintenance dose expressed in μg/kg
1.5 /h, with a 50% reduction of the maintenance dose in newborns younger than 10 days, results in a narrow range of morphine and metabolite serum concentrations throughout the studied age range. Future pharmacodynamic investigations are needed to reveal target concentrations in this population, after which final dosing recommendations can be made. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.